Improving the treatment of schizophrenia: Focus on serotonin (5-HT)(1A) receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 3, 2000, Pages 853-861

  Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MAZAPERTINE; NEUROLEPTIC AGENT; PEROSPIRONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

COGNITIVE DEFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIMBIC SYSTEM; NEGATIVE SYNDROME; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

AFFECT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION; HUMANS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SCHIZOPHRENIA;

EID: 0033696731     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. 5-HT(1A) receptor agonist properties of the antipsychotic, nemonapride: Comparison with bromerguride and clozapine
2. 5-HT(1A) agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain
3. A review of central 5-HT receptors and their function
4. 2 antagonists/5-HT1A partial agonists with potential as atypical antipsychotic agents
5. 5-HT antagonists attenuate MK801-impaired radial arm maze performance in rats
6. Cognitive deficit in schizophrenia and its neurochemical basis
7. New insights into the biology of schizophrenia through the mechanism of action of clozapine
8. 5-HT(1A) and 5-HT(2A) receptor mRNAs and binding site densities are differentially altered in schizophrenia
9. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia
10. S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT(1A) receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine
11. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates
12. The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat
13. Occupancy of 5-HT(1A) receptors by clozapine revealed by positron emission temography in the primate brain
14. Effects of atypical antipsychotic agents on social behavior in rodents
15. Adverse effects of antipsychotic agents. Do newer agents offer advantages?
16. The effects of the 5-hydroxytryptamine(1A) agonist 8-hydroxy-2-(di-n-prepylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: A microanalysis of locomotor activity
17. Knock-out mice reveal opposite roles for 5-HT(1A) and 5-HT(1B) receptors in prepulse inhibition
18. The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia
19. Single restraint stress sensitizes acute chewing movemerits induced by haloperidol, but not if the 5-HT(1A) agonist 8-OH-DPAT is given prior to stress
20. Effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) after repeated administration on a conditioned avoidance response (CAR) in the rat
21. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives
22. Pharmacologic strategies for augmenting cognitive performance in schizophrenia
23. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study
24. Modulation of cocaine-induced locomotor activity, rears and head bobs by application of WAY100635 into the dorsal and median raphe nuclei of the rat
25. (R)8-OH-DPAT, a 5-HT(1A) agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens
26. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
27. The effect of serotenin(1A) receptor agonism on antipsychotic drug-induced dopamine in rat striatum and nucleus accumbens
28. Movement disorders and new azapirone anxiolytic drugs
29. 2 occupancy, clinical response and side effects: A double-blind PET study of first-episode schizophrenia
30. Dopamine, the prefrontal cortex and schizophrenia
31. 2 antagonists on inherited catalepsy in rats
32. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia
33. 2 receptor mediated catalepsy in mice
34. Cognition, schizophrenia, and the atypical antipsychotic drugs
35. 5-HT system and cognition
36. Aggression, anxiety and vocalizations in animals: GABA(A) and 5-HT anxiolytics
37. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: Importance of nucleus accumbens 5-HT(2A) sites for PCP-induced locomotion in the rat
38. S16924 ((R)-2-{1-[2-(2,3-dihydrobenzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3y1}-1 -(4-fluoro-phenyl)-ethanone], a novel, potential antipsychotic with marked serotonin (5HT)(1A) agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol
39. Reciprocal autoreceptor and heteroreceptor control of serotonergic dopaminergic and noradrenergic transmission in the frontal cortex relevance to the actions of antidepressant agents
40. S16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)ethyl]-pyrrolidin-3y1}-1 -(4-fluoro-phenyl)-ethanone], a novel, potential antipsychotic with marked serotonin (5-HT)(1A) agonist properties: II. Functional profile in comparison to clozapine and haloperidol
41. Blockade of the discriminative stimulus effects of d-amphetamine in rhesus monkeys with serotonin 5-HT(1A) agonists
42. 35S]GTPγS binding study
43. Serotonin modulation of catalepsy induced by N(G)-nitro-L-arginine in mice
44. Do atypical antipsychotic agents interact with 5-HT(1A) receptors and monoamine uptake sites in vivo
45. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects
46. Attenuation of haloperidol-induced catalepsy by 5-HT(2C) receptor antagonists
47. Neurotrophic effects of ipsapirone and other 5-HT(1A) receptor agonists on septal cholinergic neurons in culture
48. The role of serotonin in schizophrenia
49. 11C]WAY-100635
50. 1 antagonists and 5-HT(1A) agonists
51. 5-HT(1A) receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of actions?
52. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
53. The 5-HT(1A) receptor system: Possible implications for schizophrenic negative symptomatology
54. 8-OH-DPAT disruption of prepulse inhibition in rats: Reversal with (+) WAY 100,135 and localization of site of action
55. Abnormal persistence of cerebellar serotonin(1A) receptors in schizophrenia suggests failure to regress in neonates
56. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: Inhibition of dorsal raphe cell firing and the role of 5-HT(1A) receptor activation
57. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour
58. Effect of adjunctive treatment with serotonin(1A) agonist tandospirone on memory functions in schizophrenia
59. Serotonergic mechanism in neuroleptic-induced catalepsy in the rat
60. Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat